| A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799) (NCT03631784) | Merck Sharp & Dohme LLC | 2018-10-19 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) (NCT03620162) | Merck Sharp & Dohme LLC | 2018-10-18 |
| Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (NCT03598608) | Merck Sharp & Dohme LLC | 2018-10-17 |
| MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) (NCT03552536) | Merck Sharp & Dohme LLC | 2018-10-07 |
| A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (NCT03516981) | Merck Sharp & Dohme LLC | 2018-10-01 |
| Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) (NCT03524118) | Merck Sharp & Dohme LLC | 2018-09-20 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) (NCT03615482) | Merck Sharp & Dohme LLC | 2018-09-14 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) (NCT03565900) | Merck Sharp & Dohme LLC | 2018-09-12 |
| A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034) (NCT03654326) | Merck Sharp & Dohme LLC | 2018-09-11 |
| A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) (NCT03493542) | Merck Sharp & Dohme LLC | 2018-08-31 |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (NCT03486873) | Merck Sharp & Dohme LLC | 2018-08-21 |
| Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001) (NCT03515824) | Merck Sharp & Dohme LLC | 2018-08-13 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) (NCT03547167) | Merck Sharp & Dohme LLC | 2018-07-16 |
| Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) (NCT03564691) | Merck Sharp & Dohme LLC | 2018-07-11 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) (NCT03480802) | Merck Sharp & Dohme LLC | 2018-07-06 |
| Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013) (NCT03569033) | Merck Sharp & Dohme LLC | 2018-07-04 |
| Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) (NCT03515837) | Merck Sharp & Dohme LLC | 2018-06-29 |
| Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) (NCT03546842) | Merck Sharp & Dohme LLC | 2018-06-29 |
| Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) (NCT03407170) | Merck Sharp & Dohme LLC | 2018-06-28 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) (NCT03480763) | Merck Sharp & Dohme LLC | 2018-06-22 |
| A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) (NCT03565068) | Merck Sharp & Dohme LLC | 2018-06-20 |
| Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) (NCT03443869) | Merck Sharp & Dohme LLC | 2018-05-03 |
| V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002) (NCT03486834) | Merck Sharp & Dohme LLC | 2018-04-30 |
| MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) (NCT03230838) | Merck Sharp & Dohme LLC | 2018-04-26 |
| Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) (NCT03425643) | Merck Sharp & Dohme LLC | 2018-04-24 |
| Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) (NCT03473925) | Merck Sharp & Dohme LLC | 2018-04-10 |
| Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (NCT03407144) | Merck Sharp & Dohme LLC | 2018-04-09 |
| MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) (NCT03217136) | Merck Sharp & Dohme LLC | 2018-04-03 |
| Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) (NCT03182907) | Merck Sharp & Dohme LLC | 2018-03-27 |
| Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) (NCT03382600) | Merck Sharp & Dohme LLC | 2018-03-26 |
| Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033) (NCT03482713) | Merck Sharp & Dohme LLC | 2018-03-16 |
| A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027) (NCT03449134) | Merck Sharp & Dohme LLC | 2018-03-14 |
| Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386) (NCT03311841) | Merck Sharp & Dohme LLC | 2018-03-01 |
| Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) (NCT03396445) | Merck Sharp & Dohme LLC | 2018-02-18 |
| Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) (NCT03374254) | Merck Sharp & Dohme LLC | 2018-02-16 |
| Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4) (NCT03143998) | Merck Sharp & Dohme LLC | 2018-02-12 |
| Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089) (NCT03351608) | Merck Sharp & Dohme LLC | 2018-02-12 |
| Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) (NCT03379506) | Merck Sharp & Dohme LLC | 2018-01-25 |
| Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146) (NCT03346070) | Merck Sharp & Dohme LLC | 2018-01-01 |
| Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145) (NCT03346057) | Merck Sharp & Dohme LLC | 2017-12-20 |
| Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120) (NCT03336502) | Merck Sharp & Dohme LLC | 2017-12-20 |
| Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) (NCT03302234) | Merck Sharp & Dohme LLC | 2017-12-14 |
| Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) (NCT03272347) | Merck Sharp & Dohme LLC | 2017-11-27 |
| Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001) (NCT03326986) | Merck Sharp & Dohme LLC | 2017-11-10 |
| Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) (NCT03284424) | Merck Sharp & Dohme LLC | 2017-10-26 |
| Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) (NCT03239873) | Merck Sharp & Dohme LLC | 2017-10-17 |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (NCT03221426) | Merck Sharp & Dohme LLC | 2017-10-09 |
| Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) (NCT03293485) | Merck Sharp & Dohme LLC | 2017-10-04 |
| Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) (NCT03158220) | Merck Sharp & Dohme LLC | 2017-09-20 |
| Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) (NCT03188523) | Merck Sharp & Dohme LLC | 2017-09-08 |